Ginkgo Bioworks Holdings annual shareholders’ equity
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings Shareholders’ Equity Growth & History (DNA)
Ginkgo Bioworks Holdings's shareholders’ equity was $508.6M for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual shareholders’ equity history
| Fiscal year | Period ended | Shareholders’ equity | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $508.6M | −$207.5M | −28.97% |
| 2024 | 2024-12-31 | $716.1M | −$381.1M | −34.73% |
| 2023 | 2023-12-31 | $1.10B | −$639.1M | −36.81% |
| 2022 | 2022-12-31 | $1.74B | $230.9M | +15.34% |
| 2021 | 2021-12-31 | $1.51B | $1.51B | +7526725.00% |
| 2020 | 2020-12-31 | $20,000 | −$501.8M | −100.00% |
| 2019 | 2019-12-31 | $501.9M | — | — |
Ginkgo Bioworks Holdings quarterly shareholders’ equity
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shareholders’ equity | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $420.3M | −$192.7M | −31.43% |
| Q1 2026 | 2026-03-31 | $443.2M | −$204.3M | −31.55% |
| Q4 2025 | 2025-12-31 | $508.6M | −$207.5M | −28.97% |
| Q3 2025 | 2025-09-30 | $559.8M | −$238.2M | −29.85% |
| Q2 2025 | 2025-06-30 | $613.0M | −$220.1M | −26.42% |
| Q1 2025 | 2025-03-31 | $647.4M | −$339.8M | −34.42% |
| Q4 2024 | 2024-12-31 | $716.1M | −$381.1M | −34.73% |
| Q3 2024 | 2024-09-30 | $797.9M | −$454.7M | −36.30% |
| Q2 2024 | 2024-06-30 | $833.1M | −$670.5M | −44.59% |
| Q1 2024 | 2024-03-31 | $987.3M | −$620.3M | −38.59% |
| Q4 2023 | 2023-12-31 | $1.10B | −$639.1M | −36.81% |
| Q3 2023 | 2023-09-30 | $1.25B | −$182.1M | −12.69% |
| Q2 2023 | 2023-06-30 | $1.50B | −$31.8M | −2.07% |
| Q1 2023 | 2023-03-31 | $1.61B | $26.8M | +1.69% |
| Q4 2022 | 2022-12-31 | $1.74B | $230.9M | +15.34% |
| Q3 2022 | 2022-09-30 | $1.43B | −$116.8M | −7.53% |
| Q2 2022 | 2022-06-30 | $1.54B | $1.53B | +30608.56% |
| Q1 2022 | 2022-03-31 | $1.58B | $1.58B | +31515.87% |
| Q4 2021 | 2021-12-31 | $1.51B | $1.51B | +7526725.00% |
| Q3 2021 | 2021-09-30 | $1.55B | — | — |
| Q2 2021 | 2021-06-30 | $5.0M | — | — |
| Q1 2021 | 2021-03-31 | $5.0M | — | — |
| Q4 2020 | 2020-12-31 | $20,000 | — | — |
Ginkgo Bioworks Holdings shareholders’ equity trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's shareholders’ equity increased from $20,000 to $508.6M, a change of $508.6M. The latest reported quarter, Q2 2026, shows $420.3M.
About the metric
What shareholders’ equity means
Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.
Calculation and source
SEC-reported shareholders’ equity
TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...